Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing

  • Johanna L. Schmidt
  • , Amy Pizzino
  • , Jessica Nicholl
  • , Allison Foley
  • , Yue Wang
  • , Jill A. Rosenfeld
  • , Lindsey Mighion
  • , Lora Bean
  • , Cristina da Silva
  • , Megan T. Cho
  • , Rebecca Truty
  • , John Garcia
  • , Virginia Speare
  • , Kirsten Blanco
  • , Zoe Powis
  • , Grace M. Hobson
  • , Susan Kirwin
  • , Bryan Krock
  • , Hane Lee
  • , Joshua L. Deignan
  • Maggie A. Westemeyer, Ryan L. Subaran, Isabelle Thiffault, Ellen A. Tsai, Terry Fang, Guy Helman, Adeline Vanderver
  • The Children's Hospital of Philadelphia
  • Children's Memorial Hospital
  • Emory University
  • Baylor College of Medicine
  • EGL Genetics
  • OPKO Health, Inc.
  • Invitae Corporation
  • Ambry Genetics
  • Alfred I. duPont Hospital for Children
  • University of California at Los Angeles
  • Natera, Inc
  • Cooper Genomics
  • University of Missouri at Kansas City
  • Biogen IDEC
  • Royal Children's Hospital
  • University of Queensland
  • University of Pennsylvania

Producción científica › revisión exhaustiva

42 Citas (Scopus)

Resumen

Leukodystrophies are a heterogeneous group of heritable disorders characterized by abnormal brain white matter signal on magnetic resonance imaging (MRI) and primary involvement of the cellular components of myelin. Previous estimates suggest the incidence of leukodystrophies as a whole to be 1 in 7,000 individuals, however the frequency of specific diagnoses relative to others has not been described. Next generation sequencing approaches offer the opportunity to redefine our understanding of the relative frequency of different leukodystrophies. We assessed the relative frequency of all 30 leukodystrophies (associated with 55 genes) in more than 49,000 exomes. We identified a relatively high frequency of disorders previously thought of as very rare, including Aicardi Goutières Syndrome, TUBB4A-related leukodystrophy, Peroxisomal biogenesis disorders, POLR3-related Leukodystrophy, Vanishing White Matter, and Pelizaeus-Merzbacher Disease. Despite the relative frequency of these conditions, carrier-screening laboratories regularly test only 20 of the 55 leukodystrophy-related genes, and do not test at all, or test only one or a few, genes for some of the higher frequency disorders. Relative frequency of leukodystrophies previously considered very rare suggests these disorders may benefit from expanded carrier screening.

Idioma originalEnglish
Páginas (desde-hasta)1906-1912
Número de páginas7
PublicaciónAmerican Journal of Medical Genetics, Part A
Volumen182
N.º8
DOI
EstadoPublished - 1 ago 2020
Publicado de forma externaSí

Huella

Profundice en los temas de investigación de 'Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing'. En conjunto forman una huella única.

Citar esto